secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001193125-24-283673
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 1.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan refinances convertible debt with up to $52.5M term loan from Silicon Valley Bank
--------------------------------------------------------------------------------

- First tranche of $32.5M drawn at closing; used to retire $17.2M existing convertible debt with K2 HealthVentures plus $2.1M exit fee.
- Second tranche of $20M available through June 30, 2026 at SVB's sole discretion.
- Interest rate is greater of 7.00% or prime minus 0.75%, capped at 9.75%; maturity September 1, 2029 with interest-only through Sept 2027 if milestones met.
- Company expects cash resources to fund operating plan into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524283673/0001193125-24-283673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524283673/d920508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-283673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer